Brain-Gut Relationship Studied In Those Suffering With Stomach Pain Or Discomfort
Brain-Gut Relationship Studied In Those Suffering With Stomach Pain Or Discomfort. A new clinical study will explore the brain-gut interaction in patients with functional dyspepsia and whether certain drugs can effectively relieve symptoms of this disorder. Functional dyspepsia is a costly and chronic disorder that can cause severe stomach pain often reported as cramping, bloating, and gas, or great discomfort or fullness after eating. The study is funded by the National Institutes of Health at six medical centers in the U.S.
Improved ADHD Identification In Adult And Female Patients Leads To Growth In ADHD Medication Use. Attention deficit hyperactivity disorder has been traditionally viewed as a childhood disorder, while ADHD in adults has been underdiagnosed and undertreated. A recent study shows that treatment rates have been increasing in all age groups, and improved identification has contributed to rapidly growing treatment rates for adults. Female patients show the greatest increase of all.
Why Persistent Acid Reflux Sometimes Turns Into Cancer. New research from scientists at UT Southwestern Medical Center and the Dallas Veterans Affairs Medical Center underscores the importance of preventing recurring acid reflux while also uncovering tantalizing clues on how typical acid reflux can turn potentially cancerous.
It's Only Heartburn..or Is It? Chronic Heartburn A Risk Factor For Precursor To Esophageal Cancer. If you have or have ever had chronic heartburn, you may be at risk for Barrett's esophagus, a serious complication of chronic, severe gastroesophageal reflux disease. Barrett's esophagus has been recognized as a major risk factor for developing cancer of the esophagus, the seventh deadliest cancer in men in the United States.
Kosan's Motilin Receptor Agonist, Licensed To Pfizer, Enters Phase 1 Clinical Trial In Gastroesophageal Reflux Disease. Kosan Biosciences Incorporated today announced that Pfizer Inc. has initiated a Phase 1 clinical trial of motilin receptor agonist PF-04548043, formerly KOS-2187, a selective and potent motilin receptor agonist being developed for the treatment of gastroesophageal reflux disease and potentially other gastrointestinal disorders.



